DelveInsight’s “Trigeminal Neuralgia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Trigeminal Neuralgia, historical and forecasted epidemiology as well as the Trigeminal Neuralgia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Trigeminal Neuralgia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Trigeminal Neuralgia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Trigeminal Neuralgia Market Insights
Trigeminal Neuralgia Overview
Trigeminal Neuralgia (TN), also known as tic douloureux, is a chronic pain condition that affects the trigeminal or fifth cranial nerve, one of the most widely distributed nerves in the head. It is a form of neuropathic pain (pain associated with nerve injury or nerve lesion), and categorized in two types: primary (idiopathic) and secondary.
Some of the key facts of the Trigeminal Neuralgia Market Report:
- The Trigeminal Neuralgia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- As per the National Organization for Rare Disorders (NORD), trigeminal neuralgia affects females slightly more often than males. Although the exact incidence is unknown, approximately 10,000–15,000 new cases occur each year in the United States
- According to a study by Lambru et al. (2020), the lifetime prevalence of TN is estimated to be 0.16%–0.3%, while the annual incidence is 4–29 per 100 000 person-years. It is more prevalent in women than in men. The incidence increases with age, with a mean age of onset of 53–57 years and range of 24–93 years in adult series
- Key Trigeminal Neuralgia Companies: Noema Pharma AG, Biohaven Pharmaceuticals, and others
- Key Trigeminal Neuralgia Therapies: Basimglurant, Rimegepant, and others
- The Trigeminal Neuralgia epidemiology based on gender analyzed that Trigeminal Neuralgia (TN) incidence is more common in females in comparison to males
Get a Free sample for the Trigeminal Neuralgia Market Report –
https://www.delveinsight.com/report-store/trigeminal-neuralgia-tn-market
Key benefits of the Trigeminal Neuralgia Market report:
- Trigeminal Neuralgia market report covers a descriptive overview and comprehensive insight of the Trigeminal Neuralgia Epidemiology and Trigeminal Neuralgia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Trigeminal Neuralgia market report provides insights on the current and emerging therapies.
- Trigeminal Neuralgia market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Trigeminal Neuralgia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Trigeminal Neuralgia market.
Download the report to understand which factors are driving Trigeminal Neuralgia epidemiology trends @ Trigeminal Neuralgia Epidemiological Insights
Trigeminal Neuralgia Market
The dynamics of the Trigeminal Neuralgia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
“To counter unmet market needs and provide better treatment choices for Trigeminal Neuralgia, several market players are working robustly either on single-agent novel molecules or on combination and dose modification of standard therapies. Several therapies are expected to be launched in the study period, likely to drive market growth during the study period.”
Trigeminal Neuralgia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Trigeminal Neuralgia Epidemiology Segmentation:
The Trigeminal Neuralgia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Trigeminal Neuralgia
- Prevalent Cases of Trigeminal Neuralgia by severity
- Gender-specific Prevalence of Trigeminal Neuralgia
- Diagnosed Cases of Episodic and Chronic Trigeminal Neuralgia
Trigeminal Neuralgia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Trigeminal Neuralgia market or expected to get launched during the study period. The analysis covers Trigeminal Neuralgia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Trigeminal Neuralgia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Trigeminal Neuralgia market share @ Trigeminal Neuralgia market forecast
Trigeminal Neuralgia Therapies and Key Companies
- Basimglurant: Noema Pharma AG
- Rimegepant: Biohaven Pharmaceuticals
Scope of the Trigeminal Neuralgia Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Trigeminal Neuralgia Companies: Noema Pharma AG, Biohaven Pharmaceuticals, and others
- Key Trigeminal Neuralgia Therapies: Basimglurant, Rimegepant, and others
- Trigeminal Neuralgia Therapeutic Assessment: Trigeminal Neuralgia current marketed and Trigeminal Neuralgia emerging therapies
- Trigeminal Neuralgia Market Dynamics: Trigeminal Neuralgia market drivers and Trigeminal Neuralgia market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Trigeminal Neuralgia Unmet Needs, KOL’s views, Analyst’s views, Trigeminal Neuralgia Market Access and Reimbursement
Table of Contents
1. Trigeminal Neuralgia Market Report Introduction
2. Executive Summary for Trigeminal Neuralgia
3. SWOT analysis of Trigeminal Neuralgia
4. Trigeminal Neuralgia Patient Share (%) Overview at a Glance
5. Trigeminal Neuralgia Market Overview at a Glance
6. Trigeminal Neuralgia Disease Background and Overview
7. Trigeminal Neuralgia Epidemiology and Patient Population
8. Country-Specific Patient Population of Trigeminal Neuralgia
9. Trigeminal Neuralgia Current Treatment and Medical Practices
10. Trigeminal Neuralgia Unmet Needs
11. Trigeminal Neuralgia Emerging Therapies
12. Trigeminal Neuralgia Market Outlook
13. Country-Wise Trigeminal Neuralgia Market Analysis (2019–2032)
14. Trigeminal Neuralgia Market Access and Reimbursement of Therapies
15. Trigeminal Neuralgia Market Drivers
16. Trigeminal Neuralgia Market Barriers
17. Trigeminal Neuralgia Appendix
18. Trigeminal Neuralgia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Trigeminal Neuralgia treatment, visit @ Trigeminal Neuralgia Medications
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services